rts logo

Positives for Verve Therapeutics Inc (VERV) as stock gains in recent trading

Verve Therapeutics Inc (NASDAQ: VERV) is -61.55% lower on its value in year-to-date trading and has touched a low of $4.90 and a high of $21.42 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The VERV stock was last observed hovering at around $5.21 in the last trading session, with the day’s gains setting it 0.15%.

Currently trading at $5.36, the stock is -4.09% and -20.23% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.26 million and changing 2.88% at the moment leaves the stock -52.57% off its SMA200. VERV registered -69.53% loss for a year compared to 6-month loss of -58.48%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a -15.72% gain in the last 1 month and extending the period to 3 months gives it a -62.83%, and is 2.10% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.19% over the week and 6.93% over the month.

Verve Therapeutics Inc (VERV) has around 255 employees, a market worth around $421.03M and $16.05M in sales. Profit margin for the company is -1226.43%. Distance from 52-week low is 9.39% and -74.98% from its 52-week high. The company has generated returns on investments over the last 12 months (-30.44%).

with sales reaching $2.4M over the same period.The EPS is expected to grow by 15.18% this year, but quarterly earnings will post 30.00% year-over-year. Quarterly sales are estimated to grow 14.70% in year-over-year returns.

Verve Therapeutics Inc (VERV) Top Institutional Holders

The shares outstanding are 81.97M, and float is at 59.82M with Short Float at 29.41%.

Verve Therapeutics Inc (VERV) Insider Activity

The most recent transaction is an insider purchase by Ashe Andrew D. SEC filings show that Ashe Andrew D. bought 76,000 shares of the company’s common stock on May 14 ’24 at a price of $6.26 per share for a total of $0.48 million. Following the purchase, the insider now owns 0.34 million shares.

Verve Therapeutics Inc disclosed in a document filed with the SEC on Apr 02 ’24 that Nickerson Joan (Chief Administrative Officer) sold a total of 1,514 shares of the company’s common stock. The trade occurred on Apr 02 ’24 and was made at $8.24 per share for $12475.0. Following the transaction, the insider now directly holds 8659.0 shares of the VERV stock.

Still, SEC filings show that on Nov 29 ’23, Dorval Allison (Chief Financial Officer) disposed off 554 shares at an average price of $11.45 for $6343.0. The insider now directly holds 4,060 shares of Verve Therapeutics Inc (VERV).

Related Posts